← Leaderboards
Jeffrey S Wagener
University Of Colorado Denver
$153,271
Attributed
$153,271
Total exposure
9
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $86.7K · FY2005–06$100K$75K$50K$25K$0
'05
'06
Funding mix
By agency
NIH$153,271 · 9
By mechanism
M01$153,271 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Stanley J Szefler$16,550,328
- Donald Ym Leung$75,548,590
- Frank J. Accurso$3,381,974
- Sally E Wenzel$36,525,494
- Nancy F Krebs$16,070,384
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectCystic FibrosisClinical ResearchHuman Therapy EvaluationPatient Oriented ResearchRespiratory Disorder ChemotherapyRespiratory InfectionsPseudomonas AeruginosaDisease /Therapy DurationDosageDrug Administration Rate /DurationDrug Delivery SystemsElastasesFecesGastrointestinal Absorption /TransportGastrointestinal Disorder ChemotherapyGastrointestinal Sign /SymptomInfant Human (0-1 Year)InflammationInhalation Drug AdministrationLongitudinal Human StudyNeutrophilOral AdministrationPreschool Child (1-5)
Grant awards (11)
ASSESSMENT OF INDUCED SPUTUM TO EVAL ANTI-INFLAMMATORY AGENTS IN PTS W/CF$16,202
M01 · FY2006 · RR · contact PI
TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH ANTIOXIDANT SOLUTION: A PILOT STUDY$5,941
M01 · FY2006 · RR · contact PI
A PHASE 2, STUDY OF ORAL THERACLEC-TOTAL IN CF$40,912
M01 · FY2005 · RR
TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH ANTIOXIDANT SOLUTION: A PILOT STUDY$26,916
M01 · FY2005 · RR
MULTICENTER, AZTREONAM FOR INHALATION IN CF PATIENTS WITH LUNG DISEASE$15,072
M01 · FY2005 · RR
DURATION OF ANTIMICROBIAL TREATMENT OF TOBI IN YOUNG CHILDREN W/CYSTIC FIBROSIS$2,692
M01 · FY2005 · RR
ASSSESSMENT OF INDUCED SPUTUM AS TOOL TO EVAL ANTI-INFLAM AGENTS IN PTS W/CF$1,077
M01 · FY2005 · RR
Oral ThereCLEC-Total in Subjects with Cystic Fibrosis$10,063
M01 · FY2004 · RR
Duration of Antimicrobial Tx of TOBI in Children w/ CF$8,945
M01 · FY2004 · RR
Aztreonam for Inhalation in CF Patients w/ Lung Disease$5,591
M01 · FY2004 · RR
EARLY BRONCHOPULMONARY INFECTION &INFLAMMATION IN INFANTS W/ CYSTIC FIBROSIS$19,860
M01 · FY2000 · RR